Bristol Myers Squibb Co (BMY): Total Assets
$90.04B
As of 2025-12-31
$87.63B
As of 2026-06-30
-2.4%
3-year compound annual growth
-5.3%
5-year compound annual growth
+11.0%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $90.04B | -2.8% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $92.60B | -2.7% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $95.16B | -1.7% | 2025-02-12, Balance as of period end |
| 2022-12-31 | $96.82B | -11.4% | 2024-02-13, Balance as of period end |
| 2021-12-31 | $109.31B | -7.7% | 2023-02-14, Balance as of period end |
| 2020-12-31 | $118.48B | n/a | 2022-02-09, Balance as of period end |
| 2020-09-30 | $125.54B | n/a | 2021-02-10, Balance as of period end |
| 2020-06-30 | $128.08B | n/a | 2021-02-10, Balance as of period end |
| 2020-03-31 | $129.28B | n/a | 2021-02-10, Balance as of period end |
| 2019-12-31 | $129.94B | n/a | 2021-02-10, Balance as of period end |
| 2019-09-30 | $57.43B | n/a | 2021-02-10, Balance as of period end |
| 2019-06-30 | $55.16B | n/a | 2021-02-10, Balance as of period end |
| 2019-03-31 | $34.83B | n/a | 2021-02-10, Balance as of period end |
| 2018-12-31 | $34.99B | n/a | 2020-02-24, Balance as of period end |
| 2018-09-30 | $33.73B | n/a | 2020-02-24, Balance as of period end |
| 2018-06-30 | $32.64B | n/a | 2020-02-24, Balance as of period end |
| 2018-03-31 | $33.08B | n/a | 2020-02-24, Balance as of period end |
| 2017-12-31 | $33.55B | n/a | 2019-02-25, Balance as of period end |
| 2017-09-30 | $33.98B | n/a | 2019-02-25, Balance as of period end |
| 2017-06-30 | $33.41B | n/a | 2019-02-25, Balance as of period end |
| 2017-03-31 | $32.94B | n/a | 2019-02-25, Balance as of period end |
| 2016-12-31 | $33.71B | n/a | 2018-02-13, Balance as of period end |
| 2016-09-30 | $33.73B | n/a | 2018-02-13, Balance as of period end |
| 2016-06-30 | $32.83B | n/a | 2018-02-13, Balance as of period end |
| 2016-03-31 | $31.89B | n/a | 2018-02-13, Balance as of period end |
| 2015-12-31 | $31.75B | n/a | 2017-02-21, Balance as of period end |
| 2015-09-30 | $31.78B | n/a | 2017-02-21, Balance as of period end |
| 2015-06-30 | $31.95B | n/a | 2017-02-21, Balance as of period end |
| 2015-03-31 | $33.58B | n/a | 2017-02-21, Balance as of period end |
| 2014-12-31 | $33.75B | n/a | 2016-02-12, Balance as of period end |
| 2014-09-30 | $33.45B | n/a | 2016-02-12, Balance as of period end |
| 2014-06-30 | $33.50B | n/a | 2016-02-12, Balance as of period end |
| 2014-03-31 | $33.42B | n/a | 2016-02-12, Balance as of period end |
| 2013-12-31 | $38.59B | n/a | 2015-02-13, Balance as of period end |
| 2013-09-30 | $36.80B | n/a | 2015-02-13, Balance as of period end |
| 2013-06-30 | $36.25B | n/a | 2015-02-13, Balance as of period end |
| 2013-03-31 | $35.96B | n/a | 2015-02-13, Balance as of period end |
| 2012-12-31 | $35.90B | n/a | 2014-02-14, Balance as of period end |
| 2012-09-30 | $36.04B | n/a | 2014-02-14, Balance as of period end |
| 2012-06-30 | $31.67B | n/a | 2014-02-14, Balance as of period end |
| 2012-03-31 | $32.41B | n/a | 2014-02-14, Balance as of period end |
| 2011-12-31 | $32.97B | n/a | 2013-02-15, Balance as of period end |
| 2011-09-30 | $32.01B | n/a | 2013-02-15, Balance as of period end |
| 2011-06-30 | $31.83B | n/a | 2013-02-15, Balance as of period end |
| 2011-03-31 | $30.85B | n/a | 2013-02-15, Balance as of period end |
| 2010-12-31 | $31.08B | +0.2% | 2012-02-17, Balance as of period end |
| 2009-12-31 | $31.01B | +5.2% | 2011-02-18, Balance as of period end |
| 2008-12-31 | $29.49B | n/a | 2010-02-19, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $133.96B | -0.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $40.75B | +3.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $40.56B | +7.4% |
Compare BMY, ABT, ABBV, PFE side by side · Screen every company in Pharmaceutical Preparations ↗